Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

PDE3A (Q14432) - Overview - Molecular Target Synopsis

Protein


PDE3A, cGMP-inhibited 3',5'-cyclic phosphodiesterase A
Enzyme Classification 3.1.4.17
UniProt Q14432

Also Known as PDE3A_HUMAN, PDE3A

Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.

Isoforms / Transcripts (Protein Coding)


Protein Length Ensembl Gene Ensembl Transcript Ensembl Protein Uniprot Isoform
1141ENSG00000172572ENST00000359062ENSP00000351957Q14432-1

Drugs


PDE3A is targeted by Approved Drugs Dyphylline, Cilostazol, Milrinone, Anagrelide, Theophylline, Pentoxifylline. (see details)
Dyphylline
Cilostazol
Milrinone
Anagrelide
Theophylline
Pentoxifylline

Sub-cellular localization


UniProt: PDE3A is active in the following subcellular-locations: membrane.
GO terms: PDE3A is active in the following subcellular-locations: cytosol, integral component of membrane.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project PDE3A has gain in 13 cell-lines, loss in 5 cell-lines and no signal in 986 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are: HS578T, TK_10, HL_60

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: HeLa, HCC2157, UACC-257

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: HeLa-S3, HUVEC, HFDPC

(see details)

3D Structures


At greater than 50% identity similarity to PDE3A there are:
2 structures (16 chains) solved
2 are solved in complex with at least one small molecule ligand



(see details)
Molecular Target 3D Synopsis

Screening and Chemistry


PDE3A has been screened with 2192 compounds (2911 bioactivities), 424 compounds have bioactivities that show binding affinity of <= 500nM (552 bioactivities). (see details)